检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李绍雪 柴进[2] 高宇[2] 刘畅[2] 程英[2] 连伟[2] 刘潇聪[2] 陈文生[1]
机构地区:[1]第三军医大学西南医院全军消化病研究所,重庆400038 [2]蚌埠医学院第一附属医院消化内科,安徽蚌埠233004
出 处:《蚌埠医学院学报》2015年第7期841-844,共4页Journal of Bengbu Medical College
基 金:国家自然科学基金项目(81100280);重庆市自然科学基金重点项目(CSTC2012jj B0079);重庆市科委攻关项目(CSTC2010AB5068)
摘 要:目的:观察藏茵陈对正常大鼠多耐药相关蛋白3(MRP3)和核受体孕烷X受体(PXR)表达的影响。方法:将10只SD大鼠随机分为藏茵陈组5只,藏茵陈100 mg·kg-1·d-1灌胃7 d;对照组5只,同体积0.9%氯化钠注射液灌胃。7 d后麻醉处死2组大鼠,取肝脏组织行HE染色检测肝脏形态变化,分别提取肝脏组织RNA、膜蛋白及核蛋白,采用实时聚合酶链式反应和蛋白免疫印迹检测膜转运蛋白MRP3和核受体PXR在转录与蛋白水平的表达变化。结果:给予藏茵陈后,与0.9%氯化钠注射液比较,未影响肝脏组织的形态结构;藏茵陈可显著刺激正常大鼠肝细胞膜转运蛋白MRP3表达(P<0.01);也可明显上调核受体PXR水平增高(P<0.01)。结论:藏茵陈刺激大鼠肝细胞膜蛋白MRP3的表达上调可能与核受体PXR途径相关。Objective:To observe the effects of Artemisiae capillaris on the expressions of muhidrug resistance-associated protein 3 (MRP3) and nuclear pregnane X receptor (PXR) in normal rat liver. Methods:Ten male Sprague-Dawley (SD) rats were randomly divided into the Artemisiae capillaris group and control group (5 rats each group). The Artemisiae capillaris group and control group were treated with gavage of Artemisiae capillaris( 100 mg·kg^-1· d^-1) and gavage of 0.9% sodium chloride. Two groups were sacrificed after 7 days. The morphological change of liver tissue was observed using HE staining, the total RNA and membrane or nuclear protein were extracted from the liver tissue of two groups. The mRNA and protein expressions of MRP3 and PXR were detected by Real- time PCR and Western blotting, respectively. Results: Compared with the control group, the morphological structure of liver tissue in Artemisiae capillaris group was not influenced. Artemisiae capillaris could significantly up-regulate the protein expressions of MRP3 and PXR in rat liver( P 〈 0.01 ). Conclusions: Artemisiae capillaris can up-regulate the expression of MRP3 and PXR in rat liver.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:13.58.73.22